



Published in final edited form as:

*J Immunol.* 2017 September 01; 199(5): 1716–1728. doi:10.4049/jimmunol.1700181.

## Control of Treg differentiation by the transcription factors Thpok and LRF

Andrea C. Carpenter<sup>1</sup>, Elizabeth Wohlfert<sup>2,3,4</sup>, Laura B. Chopp<sup>1,6</sup>, Melanie S. Vacchio<sup>1</sup>, Jia Nie<sup>1</sup>, Yongmei Zhao<sup>5</sup>, Jyoti Shetty<sup>5</sup>, Qi Xiao<sup>1</sup>, Callie Deng<sup>1</sup>, Bao Tran<sup>5</sup>, Margaret Cam<sup>7</sup>, Matthias M. Gaida<sup>1,8</sup>, Yasmine Belkaid<sup>2,3</sup>, and Rémy Bosselut<sup>1,\*</sup>

<sup>1</sup>Laboratory of Immune Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

<sup>2</sup>NIAID Microbiome Program, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.

<sup>3</sup>Mucosal Immunology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.

<sup>5</sup>Center for Cancer Research Sequencing Facility, Advanced Technology Research Facility, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland, USA.

<sup>6</sup>Immunology Graduate Group, University of Pennsylvania Medical School, Philadelphia, Pennsylvania, USA.

<sup>7</sup>Center for Cancer Research Collaborative Bioinformatics Resource, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

<sup>8</sup>Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.

### Abstract

The CD4<sup>+</sup>-lineage specific transcription factor Thpok is required for intrathymic CD4<sup>+</sup> T cell differentiation and, together with its homolog LRF, supports CD4<sup>+</sup> T cell helper effector responses. However, it is not known if these factors are needed for the T regulatory (Treg) arm of MHC-II responses. Here, by inactivating in mice the genes encoding both factors in differentiated Tregs, we show that Thpok and LRF are redundantly required to maintain the size and functions of the post-thymic Treg pool. They support IL 2-mediated gene expression and the functions of the Treg-specific factor Foxp3. Accordingly, Treg-specific disruption of *Thpok* and *Lrf* causes a lethal inflammatory syndrome similar to that resulting from Treg deficiency. Unlike in conventional T cells, Thpok and LRF functions in Tregs are not mediated by their repression of the transcription factor Runx3. Additionally, we found Thpok needed for the differentiation of thymic Treg

\*Address for correspondence: Rémy Bosselut, Laboratory of Immune Cell Biology, NCI, NIH, Building 37, Room 3032, 37 Convent Drive, Bethesda, MD 20892-4259, USA, phone 240-760-6866, fax 240-541-4483, remy@helix.nih.gov.

<sup>4</sup>Current Address Department of Microbiology and Immunology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, SUNY, Buffalo, NY, USA.

### Competing financial interests

The authors declare no competing financial interests.

precursors, an observation in line with the fact that Foxp3<sup>+</sup> Tregs are CD4<sup>+</sup> cells. Thus, a common Thpok-LRF node supports both helper and regulatory arms of MHC-II responses.

---

## Introduction

MHC II-restricted CD4<sup>+</sup> T cells are essential for both immune responses and immune tolerance: in addition to a profound immunodeficiency, patients with CD4<sup>+</sup> T cell lymphopenia or defective MHC-II expression experience auto-immune manifestations (1). Although seemingly paradoxical, auto-immunity in this context reflects the critical role of MHC II-restricted CD4<sup>+</sup> regulatory T cells (Treg)(2–4) for immune homeostasis. Most of these cells require the transcription factor Foxp3 for their differentiation and function (5–8); indeed, both in humans and mice, Foxp3 mutations cause a severe, early onset auto-immune syndrome affecting the endocrine system, skin and gut (9, 10). Tregs develop in the thymus from CD4<sup>+</sup> single positive (SP) thymocytes, and from naïve post-thymic CD4<sup>+</sup> T cells upon TGFβ signaling (11, 12). They constitutively express the IL-2 receptor α chain (CD25), which associates with the β and common γ chains to form the high affinity IL-2 receptor required for Treg cell differentiation and function (13). Among other functions, Foxp3 serves to sustain expression of CD25 ensuring Treg cell responsiveness to IL-2.

The zinc finger transcription factor Thpok (14, 15) is expressed in CD4<sup>+</sup> but not CD8<sup>+</sup> T cells and couples CD4<sup>+</sup> T cell differentiation to MHC-II restriction in the thymus (14, 16). It is also important for the differentiation of post-thymic CD4<sup>+</sup> T cells into cytokine-producing effectors, including type 1 and type 2 helper cells (Th1 and Th2 cells, defined by the production of IFNγ and IL-4, respectively) (17, 18). In contrast, although Thpok is expressed in Foxp3<sup>+</sup> Tregs (19), there is little evidence that it is needed for their function. While it has been reported that Thpok maintains Treg stability in the gut mucosa (20), it is not known how immune homeostasis depends on Treg expression of Thpok. Thpok disruption, whether specifically induced in Tregs (20) or enforced in all T cells, does not cause detectable auto-immune or inflammatory disease. However, these previous studies did not address the functional overlap between Thpok and the related transcription factor LRF, which serves redundantly with Thpok to promote helper T cell differentiation and functions (17, 18).

To study the impact of these factors on Treg functions, we inactivated the genes encoding Thpok and LRF (*Zbtb7b* and *Zbtb7a*, called *Thpok* and *Lrf* here, respectively) in Tregs. We demonstrate that Thpok and LRF promote Treg survival and homeostasis and are essential for Foxp3-directed gene expression. Accordingly, Treg-specific disruption of *Thpok* and *Lrf* causes a lethal inflammatory syndrome similar to that of *Scurfy* mice. Furthermore, gene expression and genetic analyses indicate that Thpok and LRF serve distinct functions in Treg and conventional T cells. Thus, Thpok and LRF are needed for regulatory MHC II-restricted T cell responses.

## Materials and Methods

### Mice

*Thpok*<sup>fl</sup> and *Thpok*<sup>GFP</sup> mice were described previously (19). *B2m*<sup>-/-</sup> (21), *Cd4*-Cre (22), Scurfy (10) animals were from Taconic, Taconic, and JAX, respectively, and CD45.1, CD45.2, and C57BL/6 mice from the NCI Animal Production Facility. *Ltr*<sup>f</sup> and *Foxp3*<sup>YFP-Cre</sup> mice were gifts from Drs. P.P. Pandolfi and A. Rudensky, respectively, and *Runx3*<sup>f</sup> and *Cd4Sif* mice from Dr. D. Littman (23–26). In experiments with *Foxp3*<sup>YFP-Cre</sup> mediated deletion, control mice were of the same gender as experimental mice and carried a single *Foxp3*<sup>YFP-Cre</sup> allele on a *Thpok*<sup>+/+</sup> *Ltr*<sup>+/+</sup> background unless specified otherwise. Transgenic mice were heterozygous for the transgene they carry. Mice were housed in specific pathogen-free facilities and analyzed between 8–16 weeks of age unless stated otherwise. All animal procedures were approved by NCI and NIAID Animal Care and Use Committees.

### Bone marrow chimeras

Bone marrow was isolated from CD45 disparate animals, T cell-depleted with Mouse Pan T (Thy1.2) Dynabeads (ThermoFisher Scientific), mixed at a 1:1 ratio and injected into lethally irradiated (900rad) recipients heterozygous for CD45.1 and CD45.2 or in a second experiment for CD45.1. Mice were analyzed at least eight weeks post transplant.

### Antibodies

The following antibodies were from either BD Pharmingen or Affymetrix eBioscience: TCR (H57-597), CD4 (RM4.4 or GK1.5), CD8 $\alpha$  (53–6.7), CD24 (M1/69), CD44 (IM7), CD62L (MEL-14), CD25 (PC61.5), CD45.1 (A20); CD45.2 (104), CD8 $\beta$  (53–5.8), MHC Class II (M5/114.15.2), IFN $\gamma$  (XMG1.2), IL-4 (11B11), IL17A (eBio17B7), Foxp3 (FJK-16S), Gata3 (L50-823), Tbet (4B10), ROR $\gamma$ t (AFKJS9), LRF (13E9), O $\times$ 40 (OX-86), GITR (DTA-1), pStat5 (47/Stat5), ICOS (7E.17G9) and Thy1.1 (HIS51). Nrp1 (3E12), Granzyme B (GB12), Runx (EPR3099), and  $\beta$ -Actin (AC-15) were from BioLegend, ThermoFisher Scientific, Abcam Epitomics and Sigma-Aldrich respectively. Immunoblotting analyses were performed as described (27), using SuperSignal West Femto Maximum Sensitivity Substrate (ThermoFisher Scientific).

### Histology and histological scores

Tissue was removed from euthanized animals, fixed in buffered formalin, embedded in paraffin, sliced and stained with hematoxylin and eosin (H&E). The resulting slides were scored from 0–2 according to methodology previously used for scoring Scurfy mice (28).

### Cell preparation and flow cytometric staining

Lymph node, thymus, spleen, siLP, and ear cells were prepared and stained as previously described (15, 19, 27). Flow cytometry data was acquired on LSRII, LSR Fortessa, LSR Fortessa X-20, and Canto II cytometers (BD Biosciences) and analyzed with FlowJo (TreeStar) software. Purification of lymphocytes by cell sorting was performed on a

FACSAriaII (BD Biosciences). Dead cells and doublets were excluded by DAPI and a combination of forward light scatter height and width gating for live cell analyses.

Analyses of intracellular cytokine expression were performed as described (19). Transcription factor expression was detected using the Foxp3/Transcription Factor Staining Buffer Set (Affymetrix eBioscience) according to the manufacturer's instructions, except for ROR $\gamma$ t and LRF staining for which the cell fixation-permeabilization step was extended to four-16 hours at 4°C and a 5-minute incubation with 2% paraformaldehyde for combined staining with YFP. Dead cells were excluded using the LIVE/DEAD Fixable Blue Dead Cell Stain Kit (ThermoFisher Scientific).

### Stat5 phosphorylation analysis

For *in vitro* Stat5 phosphorylation analyses, splenocytes were incubated with IL-2 and LiveDead Blue for 30 minutes at 37°C, fixed with 4% PFA in PBS for 10 minutes, permeabilized in 90% methanol for 30 minutes on ice, stained with anti-pStat5 and processed for flow cytometry.

*Ex vivo* Stat5 phosphorylation was conducted essentially as previously described (29). Briefly, axillary, brachial, and inguinal lymph nodes were removed two at a time, and immediately processed through a 70  $\mu$ m filter into a 4% PFA PBS solution. After a 10 min incubation, cells were washed once in PBS, resuspended in ice-cold 90% methanol, and incubated overnight at -20 degrees. The following day, cells were stained with anti-pSTAT5 or isotype control for 1 hour at room temperature, washed, and processed for flow cytometry.

### In vitro cell analyses

Retroviral transductions were performed as previously described (19), using either MIGR-mFoxP3 (a gift from Dr. Dan Littman [Addgene plasmid # 24067]) or PMRX-Thy1.1-mFoxP3, except activation was performed with only anti-CD3 $\epsilon$ , and without IL-2 supplementation. Annexin V staining was performed with the PE-Annexin V staining kit (BD Biosciences) on cells incubated for 3 hours at 37°C or 4°C in medium. Suppression assays were performed as previously described (18).

### Infections

*L. major* infections were performed as described (30) with  $5 \times 10^4$  *L. major* clone V1 metacyclic promastigotes by intradermal ear injection. Skin lesions were measured at indicated time points, and animals were subsequently euthanized. Cells were harvested from the infected ear and draining lymph node as described (31).

### RNAseq

Total lymph node and spleen cells from dKO, animal control and genetic control female mice were stained for MHC Class II and CD25, and double-sorted to prepare YFP<sup>+</sup> MHC Class II<sup>-</sup> (dKO and genetic control) or YFP<sup>-</sup> MHC Class II<sup>-</sup> CD25<sup>+</sup> (animal control) cells. Mutant samples yielded an average total of 10,000 cells and purity was >97%. RNA was prepared from pelleted cells using the RNeasy Plus Micro kit (Qiagen). From an average

total of 2ng RNA per sample, 100pg RNA (RIN values of >9.6) was put through the SMARTer Ultra Low Input RNA Kit for Illumina Sequencing (Clontech Laboratories, Inc.) according to the manufacturer's instructions. The resulting libraries were then sequenced on Illumina's HiSeq 2500 Sequencing System. For each genotype, data is derived from four biological replicates (mice) processed separately from cell sorting to sequencing; two of which (per genotype) were merged together into a single sample prior to bioinformatics analyses to achieve consistency in read numbers, whereas the other two were processed each as a single sample. This resulted in three separate samples for each genotype, as shown in Tables S1 and S2. Raw RNAseq fastq reads were aligned to mouse genome (mm10) using STAR (v. 2.4.0h) on 2-pass mode with mouse gencode (release 4) gtf (32). Genes were subsequently counted using Rsubread and analyzed for gene expression changes using limma-voom with quantile normalization (33, 34). The gene and sample-specific normalization factors were then used to correct counts to generate bedgraph files used for further visualization. RNAseq data has been deposited in the NCBI Gene Expression Omnibus (<https://www.ncbi.nlm.nih.gov/geo/>) under accession number GSE85532.

### Statistical analyses

Statistical analyses were performed using Prism (GraphPad Software, Inc.). Bars in graphs indicate average  $\pm$  s.e.m. Significance on bar plots was determined using an unpaired t-test with Welch's correction except where indicated otherwise; when significant, levels (P-values) are indicated on figures. Significance on survival curves was assessed using Log-rank (Mantel-Cox) test and Gehan-Breslow-Wilcoxon test.

## Results

### Thpok promotes thymic but not induced Treg differentiation

We previously found that germline or T cell-targeted disruption of *Thpok*, which causes MHC II-restricted thymocytes to develop into CD8<sup>+</sup> T cells (14, 16), reduces peripheral Treg numbers (19), and that disruption of both *Thpok* and the *Thpok*-related factor LRF resulted in an almost complete absence of Tregs in peripheral lymphoid organs (18). To examine if this resulted from impaired thymic Treg development, we analyzed *Thpok*<sup>fl/fl</sup> mice carrying a *Cd4-Cre* transgene (22), which deletes in CD4<sup>+</sup>CD8<sup>+</sup> thymocytes. *Thpok* disruption reduced the numbers of Treg thymocytes, and their expression of the Treg marker Ox40 (Fig. 1AB). *Thpok*-deficient precursors minimally contributed to Treg thymocyte populations in competitive mixed (wild-type: *Thpok*<sup>fl/fl</sup> *Cd4-Cre*, 1:1) bone marrow chimeras (Fig. 1C). Thus, *Thpok* is needed for the fitness of Treg precursors in the competitive environment that characterizes their intrathymic differentiation (35). While deletion of LRF *per se* had no effect on Treg thymocyte development (data not shown), deletion of both *Thpok* and LRF, in *Thpok*<sup>fl/fl</sup> *Lrf*<sup>fl/fl</sup> *Cd4-Cre* mice, had a greater impact than deletion of *Thpok* only on Treg thymocyte numbers and their expression of Ox40 (Fig. 1B, D). We conclude from these experiments that *Thpok* is needed for thymic Treg differentiation, with modest functional overlap with LRF.

Most thymic Tregs are thought to differentiate from CD25<sup>+</sup> Foxp3<sup>-</sup> precursors. We found that the percentage of such precursors was reduced in *Thpok*-deficient thymi (Fig. 1E).

Expression of TNF-family receptors Ox40 and GITR is important for intrathymic Treg differentiation (36). We found that expression of both molecules was reduced in *Thpok*-deficient CD25<sup>+</sup> Foxp3<sup>-</sup> precursors, and that this effect was amplified by the additional deletion of LRF, which on its own had no effect (Fig. 1FG and data not shown). The fact that such cells do not express Foxp3 indicates that the impact of *Thpok* on Ox40 or GITR expression is not mediated by its effect on Foxp3 expression. We conclude from these experiments that *Thpok* is involved in the generation of thymic Treg precursors, prior to *Foxp3* expression.

In addition to thymus-generated Tregs, conventional naïve CD4<sup>+</sup> T cells can be induced to express Foxp3<sup>+</sup> and acquire regulatory functions when signaled by TGFβ (11, 12). Thus, we examined if post-thymic *Thpok* disruption would affect TGFβ-induced Foxp3<sup>+</sup> expression and Treg differentiation. We purified CD4<sup>+</sup> T cells from *Thpok*<sup>fl/fl</sup> mice carrying a previously described *CD2-Cre* transgene that becomes active in post-thymic CD4<sup>+</sup> T cells (17). *Thpok* disruption did not impair, and in fact slightly enhanced, TGFβ-induced Foxp3 up-regulation (Fig. S1A). Thus, unlike for thymic Treg differentiation, *Thpok* is not needed for induced Treg differentiation.

### **Thpok requirement for thymic Treg differentiation is independent of its effect of CD4 expression**

*Thpok* promotes CD4 expression in MHC II-signaled thymocytes, by antagonizing the expression or function of Runx molecules (37, 38). Because Treg differentiation requires TCR signaling and because CD4 promotes MHC II-induced TCR signaling, we considered that termination of CD4 expression in *Thpok*-deficient thymocytes could be responsible for their impaired Treg differentiation. Consistent with this idea, most of the few Tregs that developed in *Cd4-Cre Thpok*<sup>fl/fl</sup> mice expressed CD4, unlike conventional MHC II-restricted thymocytes that become CD8<sup>+</sup> T cells (Fig. 1H). To evaluate this possibility, we generated *Cd4-Cre Thpok*<sup>fl/fl</sup> *Cd4Si*<sup>fl/+</sup> mice, in which Cre excises floxed alleles of *Thpok* and of the *Cd4* silencer (*Cd4Si*), a cis-regulatory element mediating *Cd4* silencing in differentiating CD8<sup>+</sup>-lineage thymocytes (39, 40). Even though silencer inactivation maintained CD4 expression, it failed to rescue Treg cell populations (Fig. 1HI). Thus, the impact of *Thpok* on Treg differentiation is not mediated solely by its effect on CD4 expression.

### **Thpok and LRF redundantly promote Treg homeostasis**

While these results demonstrated the importance of *Thpok* for Treg development, *Cd4-Cre* disruption could not address whether *Thpok* was needed in post-thymic Tregs, because *Thpok* is essential for conventional CD4<sup>+</sup> T cell function (17, 18, 41). To overcome this obstacle, we generated *Thpok*<sup>fl/fl</sup> mice carrying a *Foxp3*<sup>YFP-Cre</sup> knockin allele (*Thpok* KO mice), which delete *Thpok* in Treg but not conventional T cells (24). Additionally, because LRF is expressed in Tregs (Fig. 2A), we generated *Foxp3*<sup>YFP-Cre</sup> *Lrf*<sup>fl/fl</sup> and *Thpok*<sup>fl/fl</sup> *Lrf*<sup>fl/fl</sup> mice (LRF KO and dKO mice, respectively) to evaluate the functional overlap between these two factors. Animals carrying *Foxp3*<sup>YFP-Cre</sup> on an otherwise wild-type background were used as controls.

Because *Foxp3* is located on chromosome X, all male Tregs express Cre and delete floxed alleles, so that immune homeostasis depends on their ability to control wild-type effectors. Both Thpok and LRF KO male mice remained healthy and had normal numbers of conventional and regulatory T cells (Fig. 2BC). In contrast, Treg-specific deletion of both *Thpok* and *Lrf* in male mice resulted in an inflammatory disease characterized by growth retardation, widespread skin lesions, and inflammation of the lung, spleen and skin (Fig. 2CD). This condition was similar to that of *Scurfy* mice, which carry a spontaneous loss-of-function *Foxp3* mutation (10); although inflammation appeared later in dKO than in *Scurfy* mice, it resulted in death within two months of age (Fig. 2B). Most conventional T cells in dKO mice were activated (CD44<sup>hi</sup> CD62L<sup>-</sup>) and produced cytokines, including IFN $\gamma$ , IL-4 and IL-17 (Fig. 2E); deletion of either *Thpok* or *Lrf* had no such effect (Fig. 2C, F, and data not shown). Thus, Treg expression of Thpok or LRF is needed for immune tolerance.

In contrast to male mice, heterozygous (*Foxp3*<sup>+YFP-Cre</sup>) *Thpok*<sup>fl/fl</sup> *Lrf*<sup>fl/fl</sup> female mice (female dKO mice) generated Tregs expressing either the *Foxp3*<sup>YFP-Cre</sup> (deleting) or *Foxp3* (non-deleting) allele, as a result of random X chromosome inactivation during development. These animals maintained immune homeostasis and did not develop disease (data not shown), indicating that Thpok-and LRF-deficient Tregs do not acquire dominant inflammatory properties.

The number of spleen Foxp3<sup>+</sup> cells was lower in dKO than control male mice (Fig. 2C). The same was true of the numbers of YFP<sup>+</sup> (i.e. Cre-expressing) spleen Tregs in female dKO mice, in which the ratio of YFP<sup>+</sup> vs. YFP<sup>-</sup> cells was lower than in control animals (Fig. 2G). This indicated a cell-intrinsic effect of the double disruption on Treg homeostasis. dKO Tregs were mostly CD4<sup>+</sup>CD8<sup>+</sup> and CD4<sup>-</sup>CD8<sup>+</sup>, with a minor CD4<sup>+</sup>CD8<sup>-</sup> component (Fig. 2H). Deletion of *Thpok* alone, but not of *Lrf*, modestly affected CD4 and CD8 expression (Fig. 2H). Thus, Thpok and LRF redundantly support the CD4<sup>+</sup>CD8<sup>-</sup> expression pattern of Tregs, as they do for conventional CD4<sup>+</sup> T cells (16, 42).

### Thpok and LRF affect Treg functions independently of Runx3 repression

In thymocytes and conventional T cells, Thpok acts by inhibiting the expression and function of the transcription factor Runx3 (16, 39, 42). dKO Tregs had increased levels of Runx3, but not of its homolog Runx1 which is expressed in wild-type Tregs (Fig. 3A). To address whether *Runx3* de-repression underpinned the dysfunction of dKO Tregs, we examined *Foxp3*<sup>YFP-Cre</sup> *Runx3*<sup>fl/fl</sup> *Thpok*<sup>fl/fl</sup> *Lrf*<sup>fl/fl</sup> male mice, in which all Tregs lack Runx3, Thpok and LRF. The incidence and progression of inflammatory disease was similar in these and dKO mice (Figs. 3B and 2B). Of note, CD4 expression was restored by *Runx3* disruption (Fig. 3C); this indicated that the impact of Thpok and LRF on Tregs is not mediated by their effect on CD4 expression, and thereby MHC II-induced TCR signaling (43, 44).

### Effect of Thpok and LRF on Treg stability

It was reported that environmental cues in the small intestine, at the interface of the epithelial layer and of the lamina propria (siLP, the main site of immune activity at steady state), repress *Thpok*, resulting in *Foxp3* silencing and conversion of Foxp3<sup>+</sup> CD4<sup>+</sup> Tregs

into Foxp3<sup>-</sup> CD4<sup>+</sup> CD8α<sup>+</sup>CD8β<sup>-</sup> ‘ex Treg’ intra-epithelial lymphocytes (IELs) (20); accordingly, inducible *Thpok* disruption resulted in the generation of Foxp3<sup>-</sup> CD4<sup>+</sup> CD8<sup>+</sup> ex-Tregs (20). Thus, we examined the impact of *Thpok* and LRF on Foxp3 expression. Foxp3<sup>+</sup> levels were not reduced by deletion of *Thpok*, LRF or both, and were minimally increased in male dKO cells (Fig. 4AB). It was possible that disruption of *Thpok* and LRF resulted in an all-or-none *Foxp3* silencing, while having no impact on *Foxp3* expression levels in cells that continue to express this gene; such ‘binary’ shut-down has previously been observed in mice lacking the *Foxp3* CNS2 cis-regulatory element (45, 46). Because *Thpok* represses CD8 expression, *Foxp3* silencing caused by *Thpok* disruption would be accompanied by expression of CD8 in the resulting Foxp3<sup>-</sup> CD4<sup>+</sup> cells. Consistent with this idea and in line with previous results (20), male *Thpok* KO mice had Foxp3<sup>-</sup> CD4<sup>+</sup>CD8<sup>+</sup> cells, especially in the siLP (Fig. 4CD). Most of these cells expressed both CD8α and CD8β (Fig. 4E), unlike previously reported CD4<sup>+</sup>CD8α<sup>+</sup> CD8β<sup>-</sup> ex Treg IELs (20). Foxp3<sup>-</sup> CD4<sup>+</sup>CD8<sup>+</sup> cells were also found in dKO male mice (Fig. 4C–E).

In line with a recent report (47), we considered that, rather than being ex Tregs, Foxp3<sup>-</sup>CD4<sup>+</sup>CD8<sup>+</sup> cells from *Thpok* KO or dKO male mice could be *bona fide* conventional CD4<sup>+</sup> T cells that had deleted *Thpok* alleles because of ectopic *Foxp3*<sup>YFP-Cre</sup> activity. Although this possibility cannot be easily distinguished from *Foxp3* silencing after *Thpok* inactivation in Tregs, we reasoned that ectopic *Foxp3*<sup>YFP-Cre</sup> expression would also inactivate *Lrf*<sup>fl</sup> alleles in conventional CD4<sup>+</sup> T cells from LRF KO (*Lrf*<sup>fl/fl</sup> *Foxp3*<sup>YFP-Cre</sup>) male mice. Because LRF deletion *per se* has no detectable impact on Treg or conventional CD4<sup>+</sup> T cell homeostasis, and can readily be detected by intra-cellular staining and flow cytometry, we used this approach to evaluate the extent of ectopic *Foxp3*<sup>YFP-Cre</sup> activity in conventional CD4<sup>+</sup> T cells. Despite complete *Lrf* inactivation in Tregs (Fig. 4F, bottom), conventional (Foxp3<sup>-</sup>) CD4<sup>+</sup> T cells from LRF KO male mice did not show evidence of *Lrf* deletion (Fig. 4F, top). This indicates that the *Foxp3*<sup>YFP-Cre</sup> allele had little if any ectopic activity, and supports the conclusion that Foxp3<sup>-</sup> CD4<sup>+</sup>CD8<sup>+</sup> cells in *Thpok* KO male mice are indicative of *Foxp3* silencing following *Thpok* inactivation.

In contrast to their male counterparts, we did not observe Foxp3<sup>-</sup> CD4<sup>+</sup>CD8<sup>+</sup> cells in *Thpok* KO or dKO female mice (Fig. 4D). Although it is possible that impaired immune homeostasis in dKO male mice contributes to destabilize *Foxp3* expression, this is unlikely to be the case in *Thpok* KO male mice, which show little if any evidence of inflammation. Rather, we favor the possibility that *Thpok* stabilizes *Foxp3* expression in a cell-intrinsic manner, but that, in female *Thpok* KO or dKO mice, the expansion of Foxp3<sup>-</sup> ex Tregs is restrained by functionally competent Tregs (expressing the wild-type *Foxp3* allele). Altogether, these observations are consistent with the idea that *Thpok* non-redundantly stabilizes *Foxp3* expression.

The absence of detectable inflammatory disease in *Thpok* KO male mice suggested that the stabilization of *Foxp3* expression by *Thpok* was not required for systemic immune homeostasis. However, it was possible that *Thpok*-deficient Tregs, while able to maintain immune homeostasis at steady state, would be overcome upon infectious challenge. To address this possibility, we evaluated the response to *Leishmania major*, an infection in which Treg cells normally restrain Th1 effectors and prevent immunopathology (48).



Although *Thpok* KO male mice showed a trend towards increased IFN $\gamma$  production by effector T cells in the draining lymph node (dLN, Fig. S1B), neither the number of Treg cells in the dLN nor disease course were reproducibly affected (Fig. S1CD). Thus, Treg disruption of *Thpok*, regardless of its effect on *Foxp3* expression, only minimally, if at all, impairs immune homeostasis. This prompted us to consider additional functions of *Thpok* and LRF in Tregs.

### Thpok and LRF promote Treg survival

The reduced numbers of Tregs in dKO mice suggested that *Thpok* and LRF supported Treg survival. To assess this possibility, we stained Tregs with a dye assessing cell death and with annexin V, which marks cells undergoing apoptosis. We found a larger fraction of dying and dead cells among dKO than control Tregs (Fig. 5A), supporting the conclusion that *Thpok* and LRF promoted Treg survival.

We next examined the impact of *Thpok* and LRF on Treg function. We previously showed that *Thpok* was dispensable for Tregs to suppress effector T cell proliferation *in vitro* (18), an observation consistent with the conserved immune homeostasis in *Thpok* KO mice. Even though the severe inflammation in dKO male mice suggested that the combined disruption of *Thpok* and LRF would affect Treg function, dKO Tregs efficiently restrained effector T cells in a conventional *in vitro* suppression assay (Fig. 5B).

### Impact of Thpok and LRF on Treg gene expression

The number of Tregs in dKO mice was insufficient to conduct *in vivo* functional assays [e.g. prevention of inflammatory colitis (49) or rescue of the *Scurfy* phenotype (5)]. Thus, we sought insight into the impact of *Thpok* and LRF on Treg function by examining how they affect gene expression, using deep sequencing of reverse-transcribed mRNA (RNAseq). To avoid the confounding effects of inflammation in male mice, these analyses were performed on female cells. We compared YFP<sup>+</sup> dKO Tregs with (i) CD25<sup>+</sup> YFP<sup>-</sup> ‘animal control’ cells, obtained from the same female mice as the YFP<sup>+</sup> Tregs but expressing the *Foxp3*<sup>+</sup> allele, and (ii) YFP<sup>+</sup> Tregs from *Foxp3*<sup>+/YFP-Cre</sup> *Thpok*<sup>+/+</sup> *Lrf*<sup>+/+</sup> female mice (‘genetic controls’ which express the *Foxp3*<sup>YFP-Cre</sup> allele). Cre activity in dKO cells resulted in a complete loss of reads from floxed *Thpok* and *Lrf* exons (Fig. S2A) (19, 23). While we found lower *Foxp3* read numbers in dKO than in *Foxp3*<sup>+</sup> animal control cells (Fig. 6AB), this was a consequence of the *Foxp3*<sup>YFP-Cre</sup> knockin strategy. Indeed, there was no difference between dKO and *Foxp3*<sup>YFP-Cre</sup> genetic control cells, which both carry the *Foxp3*<sup>YFP-Cre</sup> knockin allele, consistent with the conserved *Foxp3*<sup>+</sup> expression in dKO cells (Fig. 6B and 4A).

Among 13702 genes with detectable RNA reads, we found 497 outliers defined by a 2-fold or greater significant expression change (P-value < 0.05); of those, 233 were over-expressed and 266 under-expressed in dKO cells relative to both animal and genetic controls (Fig. 6A and Tables S1, S2). We first examined whether these outlier genes were related to previously reported *Thpok*- or *Foxp3*-dependent ‘signatures’ (17, 50). Aside from *Cd4*, *Cd8*, and *Runx3*, there was little overlap between outlier genes in dKO Tregs and the *Thpok* signature previously identified in Th1 effector cells (Fig. S2BC). Unexpectedly, the intersection with the Treg signature was similarly limited (Fig. 6C), and notably included *Nrp1* and *Tnfrsf4*

(encoding O<sub>x</sub>40). In addition to these intersections with Thpok and Foxp3<sup>+</sup> signatures, the under expressed set comprised multiple genes important for immune response (Fig. 6B, D, E and S2D), including *Icos* and *Il2ra* (encoding CD25, the IL-2 receptor  $\alpha$  chain). Accordingly, parsing the under expressed gene list with the metascape search tool (51) revealed significant enrichment with IL-2 and Stat5 targets, indicating that Thpok and LRF redundantly support IL-2-mediated gene expression in Tregs (Fig. S2EF). Of note, no consistent association emerged from the over-expressed gene list (data not shown). Thus, the impact of Thpok and LRF on Treg gene expression is distinct from that of Foxp3, or from their impact in conventional T cells.

To examine if the reduced expression of IL-2 target genes resulted from impaired transduction of IL-2 signals, we assessed phosphorylation of the IL-2 signaling relay Stat5. We found no evidence of impaired Stat5 phosphorylation in YFP<sup>+</sup> Tregs from female dKO mice after *in vitro* IL-2 stimulation (Fig. 6F). In contrast, we found reduced levels of phosphorylated Stat5 (pStat5) in *ex vivo* Tregs fixed immediately after disruption of peripheral LN to assess *in vivo* IL-2 signaling (Fig. 6G) (29). Of note, the difference in *in vivo* Stat5 phosphorylation between wild-type and dKO Tregs varied among experiments. Together with the conserved IL-2-induced Stat5 phosphorylation *in vitro*, this suggests that the impact of Thpok and LRF on IL-2 target genes could be indirect, e.g. resulting from impaired access to IL-2 producing cells, rather than reflecting a cell-intrinsic impairment of IL-2 signal transduction. Consistent with this scenario, Thpok and LRF disruption affected the expression of genes involved in cell migration (Fig. S2G).

Despite the reduced survival of dKO Tregs, there was little effect of Thpok and LRF disruption on expression of cell-death related genes (Fig. S2D). In contrast, dKO cells had reduced expression of genes associated with cell migration and effector differentiation, including *Tbx21* (encoding T-bet) and *Cxcr3*, which characterize a population of ‘Th1-like’ Tregs (52), and *Batf*, *Rora*, *Il6ra*, and *Ccr6*, characteristic of ‘Th17-like’ Tregs (Fig. 7A, Fig. S2D, G) (53, 54). Consistent with this impact, the frequency of CD44<sup>hi</sup> CD62L<sup>-</sup> effector Tregs, which normally includes all Cxcr3<sup>+</sup> Tregs, was significantly reduced among YFP<sup>+</sup> dKO Tregs in female mice (Fig. 7BC). Additionally, the number of siLP Tregs, most of which are effector Tregs, was strongly reduced in dKO male mice (Fig. 7D). In contrast, it was not affected by the deletion of *Thpok* only, unlike what was observed after inducible *Thpok* disruption (20). This difference may be due at least in part to the inclusion of CD8 $\beta$ -expressing Foxp3<sup>+</sup> Tregs in data shown in Fig. 7D, unlike in that previous study (20). Additionally, it is possible that compensatory mechanisms maintain Treg numbers at steady-state despite *Thpok* disruption, but not after acute induced deletion (20). Altogether, we conclude from these findings that Thpok and LRF contribute to the differentiation or competitive fitness of effector Tregs.

To independently document the impact of Thpok and LRF on Treg-specific gene expression, we examined whether these factors are needed to allow Foxp3-induced expression of CD25 and Nrp1, two genes characteristic of Tregs (13, 55, 56) and under-expressed in dKO cells (Fig. 6DE). We retrovirally transduced Foxp3 in conventional T cells, either Thpok- and LRF-sufficient (CD4<sup>+</sup> and CD8<sup>+</sup> T cells from wild-type mice) or Thpok- and LRF-deficient (CD8<sup>+</sup> T cells from *B2m*<sup>-/-</sup> *Thpok*<sup>fl/fl</sup> *Lrf*<sup>fl/fl</sup> *Cd4*-Cre mice, which all are MHC II-

restricted). Whereas Foxp3 transduction up-regulated Nrp1 and CD25 in wild-type CD4<sup>+</sup> and CD8<sup>+</sup> T cells, this effect was blunted by disruption of Thpok and LRF (Fig. 8). Thus, Thpok and LRF are important for Foxp3-induced expression of Treg-specific genes.

In summary, we demonstrate that the transcription factor Thpok is needed for the thymic differentiation of Treg cells, and, redundantly with its homolog LRF, for Treg-mediated immune homeostasis. Both factors act in Tregs by supporting Foxp3-directed gene expression, notably by enabling expression of IL-2-dependent genes and the development of effector Treg populations.

## Discussion

Here, we report that overlapping functions of the transcription factors Thpok and LRF are critical for the differentiation and homeostasis of Foxp3<sup>+</sup> Treg cells, as shown by the severe breach of tolerance resulting from their Treg-specific disruption. Additionally, we show that these factors support intrathymic Treg development.

Although there are CD8<sup>+</sup> Foxp3<sup>-</sup> Treg cells (57), Foxp3<sup>+</sup> Tregs are invariably CD4<sup>+</sup>. Why this is the case has remained unclear, notably because the *Foxp3* locus is epigenetically open in CD4<sup>+</sup>CD8<sup>+</sup> (double positive, DP) thymocytes (58), which serve as precursors of both CD4<sup>+</sup> and CD8<sup>+</sup> cells (59). Thpok is required for the differentiation of conventional MHC II-restricted thymocytes into CD4<sup>+</sup> T cells, but not for their positive selection. That is, Thpok-deficient MHC II-restricted thymocytes differentiate into CD8<sup>+</sup> instead of CD4<sup>+</sup> T cells (14, 16); importantly, despite such lineage 'redirection', the number and repertoire of MHC II-restricted T cells are not detectably affected by Thpok disruption (18, 19, 60). In contrast, we show here that Thpok is needed for the development of thymic Treg precursors, and not solely for their CD4<sup>+</sup>-lineage differentiation. Because the development of thymic Tregs is thought to require high-intensity TCR signaling, we considered that Thpok promoted Treg development by supporting expression of CD4, which contributes to TCR signaling. Unexpectedly, this was not the case, as the requirement for Thpok is not relieved by enforced expression of CD4.

Given the role of Thpok in stabilizing Foxp3 expression in intestinal Tregs (20), it is possible that Thpok contributes to Foxp3 expression in thymocytes. However, the fact that Thpok is needed for the proper differentiation of CD25<sup>+</sup> Foxp3<sup>-</sup> thymic Treg precursors indicates that it serves at least in part independently of a potential direct effect on *Foxp3*. Chromatin immunoprecipitation analyses, which we could not perform with currently available reagents, will help address this issue. Of note, TNF-family receptors, including GITR and Ox40, promote Treg differentiation in the thymus at least in part by facilitating IL-2 signaling (36). We found expression of both receptors to be Thpok-dependent in thymocytes. Thus, it is possible that, through its effect on TNF-family receptor expression, Thpok serves in thymocytes to facilitate IL-2-mediated gene expression. Additionally, it is possible that Thpok promotes Treg thymocyte differentiation by antagonizing the activity of Runx molecules; however, the functional overlap between Runx1 and Runx3 (61), together with the dependence of Tregs on Runx activity (62, 63), create a major challenge to experimental investigations of this hypothesis.

Contrary to the importance of Thpok *per se* for thymic Treg development, we found that Thpok and LRF served redundantly in post-thymic Tregs to support the functions and homeostasis of these cells. Previous studies have identified components of the transcriptional network supporting Treg differentiation and functions. These include factors enabling Foxp3-mediated gene expression (64), factors enforcing Foxp3 expression and Treg fitness, including Gata3 (65, 66), Nur77-family members (67–69), the chromatin modifier Ezh2 (70), or the pathway activated by PI-3 kinase activity and targeting Foxo transcription factors and the metabolic regulator mTOR (reviewed in 71, 72). Our study supports the conclusion that the main function of Thpok and LRF in post-thymic Tregs is to support Foxp3-mediated gene expression rather than to maintain expression of Foxp3 itself.

This conclusion appears at odds with our observation, and a previous report (20), that Thpok contributes to stabilize *Foxp3* expression, with little functional overlap with LRF. It was previously reported that, through this activity, Thpok prevents the conversion of siLP Foxp3<sup>+</sup> CD4<sup>+</sup>CD8<sup>-</sup> Tregs into Foxp3<sup>-</sup> CD4<sup>+</sup> CD8 $\alpha$ <sup>+</sup> CD8 $\beta$ <sup>-</sup> IELs (20). However, despite this impact on *Foxp3* expression, Thpok is not needed for Tregs to enforce systemic immune homeostasis or for their responses to infection. Even in the gut mucosal environment, Thpok is dispensable for the prevention of intestinal inflammation in a model of antigen-induced colitis (20). Of note, disruption of the *Foxp3* CNS2 *cis*-regulatory element, which destabilizes *Foxp3* expression but does not affect the function of remaining Foxp3<sup>+</sup> Treg cells, has a much milder impact on immune homeostasis than disruption of Thpok and LRF (45, 46).

The functions of Thpok and LRF in Tregs differ in three important respects from those in conventional CD4<sup>+</sup> T cells. First, the functional overlap between the two factors is broader in Tregs than in conventional effector T cells. Whereas Thpok *per se* is largely dispensable for Treg functions, it is needed for proper Th1 and Th2 responses with little compensation, if any, by LRF (17). Second, the functional targets of Thpok and LRF differ in Treg and conventional CD4<sup>+</sup> effector T cells. Whereas in conventional CD4<sup>+</sup> T cells Thpok inhibits the expression of cytotoxic genes (17, 27), many of these genes, including that for Granzyme B, are normally expressed in Tregs despite Thpok expression (73, 74). Conversely, whereas Thpok promotes expression of genes typical of helper differentiation in conventional CD4<sup>+</sup> T cells, including *Cd40lg*, *S1pr1* and *Btla* (17), these genes are not affected by inactivation of Thpok and LRF in Tregs. Genome-wide analyses of Thpok DNA binding by chromatin immunoprecipitation will assist in determining if such differences reflect distinct repertoires of Thpok binding sites among T cell subsets. Third, the key functions of Thpok and LRF in Tregs are not mediated by inhibition of Runx3 expression or activity. This conclusion is in line with the ability of Foxp3 itself to antagonize Runx activity and notably restrain Runx-mediated expression of IL-2 and IFN $\gamma$  (75). Indeed, Runx activity is critical in Tregs, as demonstrated by Treg-specific disruption of Cbfb, an obligate Runx cofactor (62, 63). Accordingly, *Foxp3*<sup>YFP-Cre</sup>-mediated disruption of Thpok, LRF and Cbfb failed to generate functional Tregs (A.C. and R.B., unpublished observations).

Although additional investigations will be needed to gain a full mechanistic understanding of the functions of Thpok and LRF in Tregs, our findings indicate that these factors redundantly promote Treg survival, and suggest that they are especially important for the

homeostasis of effector Tregs, a subset whose importance is increasingly appreciated (76–78). Effector Tregs express transcription factors, including T-bet, Batf and ROR $\alpha$ , that in conventional helper T cells direct expression of inflammatory cytokines, but they do not express the corresponding cytokines (e.g. IFN $\gamma$  or IL-17)(52, 76). Their chemokine receptor expression matches that of conventional effector T cells and targets them to inflammation sites, where they could serve as ‘sinks’ for inflammatory cytokines (e.g. IL-6 or IL-12) for which they carry receptors. Accordingly, there is evidence that effector Treg cells serve to control specific conventional T cell responses (79, 80). Effector Tregs are abundant at mucosal interfaces and in tissues, whereas naïve Treg cells, which do not express effector transcription factors, predominate in peripheral lymphoid organs at steady state.

Although Thpok and LRF are not strictly required for effector Treg differentiation, our findings are most consistent with a scenario whereby these factors redundantly promote the survival of Tregs when they acquire ‘effector’ functions. In this perspective, Tregs lacking Thpok and LRF are eliminated in a competitive setting (in female mice in the experimental systems used in the present study), resulting in the preponderance of wild-type Tregs which ensure immune homeostasis. In contrast, in a non-competitive setting (in male mice in the experimental systems used in the present study), Thpok and LRF deficiency results in a loss of Treg function and rupture of immune tolerance. The paucity of dKO Treg cells in siLP, where most Tregs have effector functions, is consistent with this scenario.

In summary, the severe breach of tolerance resulting from the Treg-specific disruption of Thpok and LRF shows that these transcription factors are critical components of the network controlling the differentiation and homeostasis of Foxp3<sup>+</sup> Tregs. Together with our previous finding that both Thpok and LRF are needed for effector differentiation of conventional CD4<sup>+</sup> T cells (17), these results demonstrate that the Thpok-LRF ‘node’ supports both the helper and regulatory arms of the MHC II-restricted response, and therefore uncovers a previously unrecognized organizational principle of the adaptive immune system.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

We thank K. Beacht for technical assistance, S. Banerjee and F. Livak for flow sorting advice, T.A. Lewis, G. Jackson for expert mouse technical support, T. Ciucci, J. Grainger, O. Harrison for useful discussions, and J. Ashwell, T. Ciucci, P. Love, and A. Sher for reading the manuscript.

### Funding Sources

Supported by the Intramural Research Programs of the National Cancer Institute, Center for Cancer Research, and of the National Institute of Allergy and Infectious Diseases, National Institutes of Health. M.M.G. was supported by the German Research Foundation (Ga 1818/2-1).

## References

1. Reith W, Mach B. The bare lymphocyte syndrome and the regulation of MHC expression. Annual review of immunology. 2001; 19:331–373.

2. Belkaid Y, Tarbell K. Regulatory T cells in the control of host-microorganism interactions (\*). *Annual review of immunology*. 2009; 27:551–589.
3. Ohkura N, Kitagawa Y, Sakaguchi S. Development and maintenance of regulatory T cells. *Immunity*. 2013; 38:414–423. [PubMed: 23521883]
4. Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. *Annual review of immunology*. 2012; 30:531–564.
5. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. *Nature immunology*. 2003; 4:330–336. [PubMed: 12612578]
6. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. *Science (New York, N.Y.)*. 2003; 299:1057–1061.
7. Khattri R, Cox T, Yasayko SA, Ramsdell F. An essential role for Scurfin in CD4+CD25+ T regulatory cells. *Nature immunology*. 2003; 4:337–342. [PubMed: 12612581]
8. Ramsdell F, Ziegler SF. FOXP3 and scurfy: how it all began. *Nature reviews. Immunology*. 2014; 14:343–349.
9. Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, Kelly TE, Saulsbury FT, Chance PF, Ochs HD. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. *Nat Genet*. 2001; 27:20–21. [PubMed: 11137993]
10. Brunkow ME, Jeffery EW, Hjerrild KA, Paepfer B, Clark LB, Yasayko SA, Wilkinson JE, Galas D, Ziegler SF, Ramsdell F. Disruption of a new forkhead/winged-helix protein, scurfy, results in the fatal lymphoproliferative disorder of the scurfy mouse. *Nat Genet*. 2001; 27:68–73. [PubMed: 11138001]
11. Lee HM, Hsieh CS. Rare development of Foxp3+ thymocytes in the CD4+CD8+ subset. *Journal of immunology (Baltimore, Md. : 1950)*. 2009; 183:2261–2266.
12. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. *The Journal of experimental medicine*. 2003; 198:1875–1886. [PubMed: 14676299]
13. Malek TR. The biology of interleukin-2. *Annual review of immunology*. 2008; 26:453–479.
14. He X, He X, Dave VP, Zhang Y, Hua X, Nicolas E, Xu W, Roe BA, Kappes DJ. The zinc finger transcription factor Th-POK regulates CD4 versus CD8 T-cell lineage commitment. *Nature*. 2005; 433:826–833. [PubMed: 15729333]
15. Sun G, Liu X, Mercado P, Jenkinson SR, Kypriotou M, Feigenbaum L, Galera P, Bosselut R. The zinc finger protein cKrox directs CD4 lineage differentiation during intrathymic T cell positive selection. *Nature immunology*. 2005; 6:373–381. [PubMed: 15750595]
16. Wang L, Bosselut R. CD4-CD8 lineage differentiation: Thpok-ing into the nucleus. *Journal of immunology (Baltimore, Md. : 1950)*. 2009; 183:2903–2910.
17. Vacchio MS, Wang L, Bouladoux N, Carpenter AC, Xiong Y, Williams LC, Wohlfert E, Song KD, Belkaid Y, Love PE, Bosselut R. A ThPOK-LRF transcriptional node maintains the integrity and effector potential of post-thymic CD4+ T cells. *Nature immunology*. 2014; 15:947–956. [PubMed: 25129370]
18. Carpenter AC, Grainger JR, Xiong Y, Kanno Y, Chu HH, Wang L, Naik S, dos Santos L, Wei L, Jenkins MK, O'Shea JJ, Belkaid Y, Bosselut R. The transcription factors Thpok and LRF are necessary and partly redundant for T helper cell differentiation. *Immunity*. 2012; 37:622–633. [PubMed: 23041065]
19. Wang L, Wildt KF, Castro E, Xiong Y, Feigenbaum L, Tessarollo L, Bosselut R. The zinc finger transcription factor Zbtb7b represses CD8-lineage gene expression in peripheral CD4+ T cells. *Immunity*. 2008; 29:876–887. [PubMed: 19062319]
20. Sujino T, London M, Hoytema van Konijnenburg DP, Rendon T, Buch T, Silva HM, Lafaille JJ, Reis BS, Mucida D. Tissue adaptation of regulatory and intraepithelial CD4+ T cells controls gut inflammation. *Science (New York, N.Y.)*. 2016
21. Zijlstra M, Bix M, Simister NE, Loring JM, Raulet DH, Jaenisch R. Beta 2-microglobulin deficient mice lack CD4-8+ cytolytic T cells. *Nature*. 1990; 344:742–746. [PubMed: 2139497]


22. Lee PP, Fitzpatrick DR, Beard C, Jessup HK, Lehar S, Makar KW, Perez-Melgosa M, Sweetser MT, Schlissel MS, Nguyen S, Cherry SR, Tsai JH, Tucker SM, Weaver WM, Kelso A, Jaenisch R, Wilson CB. A critical role for Dnmt1 and DNA methylation in T cell development, function, and survival. *Immunity*. 2001; 15:763–774. [PubMed: 11728338]
23. Maeda T, Merghoub T, Hobbs RM, Dong L, Maeda M, Zakrzewski J, van den Brink MR, Zelent A, Shigematsu H, Akashi K, Teruya-Feldstein J, Cattoretti G, Pandolfi PP. Regulation of B versus T lymphoid lineage fate decision by the proto-oncogene LRF. *Science (New York, N.Y.)*. 2007; 316:860–866.
24. Rubtsov YP, Rasmussen JP, Chi EY, Fontenot J, Castelli L, Ye X, Treuting P, Siewe L, Roers A, Henderson WR Jr, Muller W, Rudensky AY. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. *Immunity*. 2008; 28:546–558. [PubMed: 18387831]
25. Naoe Y, Setoguchi R, Akiyama K, Muroi S, Kuroda M, Hatam F, Littman DR, Taniuchi I. Repression of interleukin-4 in T helper type 1 cells by Runx/Cbf beta binding to the Il4 silencer. *The Journal of experimental medicine*. 2007; 204:1749–1755. [PubMed: 17646405]
26. Leung RK, Thomson K, Gallimore A, Jones E, Van den Broek M, Sierro S, Alsheikhly AR, McMichael A, Rahemtulla A. Deletion of the CD4 silencer element supports a stochastic mechanism of thymocyte lineage commitment. *Nature immunology*. 2001; 2:1167–1173. [PubMed: 11694883]
27. Wang L, Wildt KF, Zhu J, Zhang X, Feigenbaum L, Tessarollo L, Paul WE, Fowlkes BJ, Bosselut R. Distinct functions for the transcription factors GATA-3 and ThPOK during intrathymic differentiation of CD4(+) T cells. *Nature immunology*. 2008; 9:1122–1130. [PubMed: 18776904]
28. Godfrey VL, Wilkinson JE, Russell LB. X-linked lymphoreticular disease in the scurfy (sf) mutant mouse. *Am J Pathol*. 1991; 138:1379–1387. [PubMed: 2053595]
29. Smigielski KS, Richards E, Srivastava S, Thomas KR, Dudda JC, Klonowski KD, Campbell DJ. CCR7 provides localized access to IL-2 and defines homeostatically distinct regulatory T cell subsets. *The Journal of experimental medicine*. 2014; 211:121–136. [PubMed: 24378538]
30. Suffia IJ, Reckling SK, Piccirillo CA, Goldszmid RS, Belkaid Y. Infected site-restricted Foxp3+ natural regulatory T cells are specific for microbial antigens. *The Journal of experimental medicine*. 2006; 203:777–788. [PubMed: 16533885]
31. Belkaid Y, Kamhawi S, Modi G, Valenzuela J, Noben-Trauth N, Rowton E, Ribeiro J, Sacks DL. Development of a natural model of cutaneous leishmaniasis: powerful effects of vector saliva and saliva preexposure on the long-term outcome of *Leishmania major* infection in the mouse ear dermis. *The Journal of experimental medicine*. 1998; 188:1941–1953. [PubMed: 9815271]
32. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics*. 2013; 29:15–21. [PubMed: 23104886]
33. Law CW, Chen Y, Shi W, Smyth GK. voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. *Genome Biol*. 2014; 15:R29. [PubMed: 24485249]
34. Liao Y, Smyth GK, Shi W. The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote. *Nucleic Acids Res*. 2013; 41:e108. [PubMed: 23558742]
35. Bautista JL, Lio CW, Lathrop SK, Forbush K, Liang Y, Luo J, Rudensky AY, Hsieh CS. Intraclonal competition limits the fate determination of regulatory T cells in the thymus. *Nature immunology*. 2009; 10:610–617. [PubMed: 19430476]
36. Mahmud SA, Manlove LS, Schmitz HM, Xing Y, Wang Y, Owen DL, Schenkel JM, Boomer JS, Green JM, Yagita H, Chi H, Hogquist KA, Farrar MA. Costimulation via the tumor-necrosis factor receptor superfamily couples TCR signal strength to the thymic differentiation of regulatory T cells. *Nature immunology*. 2014; 15:473–481. [PubMed: 24633226]
37. Wildt KF, Sun G, Grueter B, Fischer M, Zamisch M, Ehlers M, Bosselut R. The transcription factor Zbtb7b promotes CD4 expression by antagonizing Runx-mediated activation of the CD4 silencer. *Journal of immunology (Baltimore, Md. : 1950)*. 2007; 179:4405–4414.
38. Muroi S, Naoe Y, Miyamoto C, Akiyama K, Ikawa T, Masuda K, Kawamoto H, Taniuchi I. Cascading suppression of transcriptional silencers by ThPOK seals helper T cell fate. *Nature immunology*. 2008; 9:1113–1121. [PubMed: 18776907]

39. Taniuchi I, Ellmeier W. Transcriptional and epigenetic regulation of CD4/CD8 lineage choice. *Advances in immunology*. 2011; 110:71–110. [PubMed: 21762816]
40. Gialitakis M, Sellars M, Littman DR. The epigenetic landscape of lineage choice: lessons from the heritability of CD4 and CD8 expression. *Current topics in microbiology and immunology*. 2012; 356:165–188. [PubMed: 21989924]
41. Reis BS, Rogoz A, Costa-Pinto FA, Taniuchi I, Mucida D. Mutual expression of the transcription factors Runx3 and ThPOK regulates intestinal CD4(+) T cell immunity. *Nature immunology*. 2013; 14:271–280. [PubMed: 23334789]
42. Vacchio MS, Bosselut R. What Happens in the Thymus Does Not Stay in the Thymus: How T Cells Recycle the CD4+CD8+ Lineage Commitment Transcriptional Circuitry To Control Their Function. *Journal of immunology (Baltimore, Md. : 1950)*. 2016; 196:4848–4856.
43. Levine AG, Arvey A, Jin W, Rudensky AY. Continuous requirement for the TCR in regulatory T cell function. *Nature immunology*. 2014; 15:1070–1078. [PubMed: 25263123]
44. Vahl JC, Drees C, Heger K, Heink S, Fischer JC, Nedjic J, Ohkura N, Morikawa H, Poeck H, Schallenberg S, Riess D, Hein MY, Buch T, Polic B, Schonle A, Zeiser R, Schmitt-Graff A, Kretschmer K, Klein L, Korn T, Sakaguchi S, Schmidt-Supprian M. Continuous T cell receptor signals maintain a functional regulatory T cell pool. *Immunity*. 2014; 41:722–736. [PubMed: 25464853]
45. Li X, Liang Y, LeBlanc M, Benner C, Zheng Y. Function of a Foxp3 cis-element in protecting regulatory T cell identity. *Cell*. 2014; 158:734–748. [PubMed: 25126782]
46. Feng Y, Arvey A, Chinen T, van der Veken J, Gasteiger G, Rudensky Alexander Y. Control of the Inheritance of Regulatory T Cell Identity by a cis Element in the Foxp3 Locus. *Cell*. 2014; 158:749–763. [PubMed: 25126783]
47. Franckaert D, Dooley J, Roos E, Floess S, Huehn J, Luche H, Fehling HJ, Liston A, Linterman MA, Schlenner SM. Promiscuous Foxp3-cre activity reveals a differential requirement for CD28 in Foxp3(+) and Foxp3(-) T cells. *Immunology and cell biology*. 2015; 93:417–423. [PubMed: 25533288]
48. Belkaid Y, Mendez S, Lira R, Kadambi N, Milon G, Sacks D. A natural model of Leishmania major infection reveals a prolonged “silent” phase of parasite amplification in the skin before the onset of lesion formation and immunity. *Journal of immunology (Baltimore, Md. : 1950)*. 2000; 165:969–977.
49. Read S, Powrie F. Induction of inflammatory bowel disease in immunodeficient mice by depletion of regulatory T cells. *Current protocols in immunology*. 2001 Chapter 15: Unit 15.13.
50. Hill JA, Feuerer M, Tash K, Haxhinasto S, Perez J, Melamed R, Mathis D, Benoist C. Foxp3 transcription-factor-dependent and -independent regulation of the regulatory T cell transcriptional signature. *Immunity*. 2007; 27:786–800. [PubMed: 18024188]
51. Tripathi S, Pohl MO, Zhou Y, Rodriguez-Frandsen A, Wang G, Stein DA, Moulton HM, DeJesus P, Che J, Mulder LC, Yanguiz E, Andenmatten D, Pache L, Manicassamy B, Albrecht RA, Gonzalez MG, Nguyen Q, Brass A, Elledge S, White M, Shapira S, Hacoheh N, Karlas A, Meyer TF, Shales M, Gatorano A, Johnson JR, Jang G, Johnson T, Verschuere E, Sanders D, Krogan N, Shaw M, Konig R, Stertz S, Garcia-Sastre A, Chanda SK. Meta- and Orthogonal Integration of Influenza “OMICs” Data Defines a Role for UBR4 in Virus Budding. *Cell host & microbe*. 2015; 18:723–735. [PubMed: 26651948]
52. Koch MA, Tucker-Heard G, Perdue NR, Killebrew JR, Urdahl KB, Campbell DJ. The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. *Nature immunology*. 2009; 10:595–602. [PubMed: 19412181]
53. Vasanthakumar A, Moro K, Xin A, Liao Y, Gloury R, Kawamoto S, Fagarasan S, Mielke LA, Afshar-Sterle S, Masters SL, Nakae S, Saito H, Wentworth JM, Li P, Liao W, Leonard WJ, Smyth GK, Shi W, Nutt SL, Koyasu S, Kallies A. The transcriptional regulators IRF4, BATF and IL-33 orchestrate development and maintenance of adipose tissue-resident regulatory T cells. *Nature immunology*. 2015; 16:276–285. [PubMed: 25599561]
54. Yamazaki T, Yang XO, Chung Y, Fukunaga A, Nurieva R, Pappu B, Martin-Orozco N, Kang HS, Ma L, Panopoulos AD, Craig S, Watowich SS, Jetten AM, Tian Q, Dong C. CCR6 regulates the migration of inflammatory and regulatory T cells. *Journal of immunology (Baltimore, Md. : 1950)*. 2008; 181:8391–8401.



55. Weiss JM, Bilate AM, Gobert M, Ding Y, Curotto de Lafaille MA, Parkhurst CN, Xiong H, Dolpady J, Frey AB, Ruocco MG, Yang Y, Floess S, Huehn J, Oh S, Li MO, Niec RE, Rudensky AY, Dustin ML, Littman DR, Lafaille JJ. Neuropilin 1 is expressed on thymus-derived natural regulatory T cells, but not mucosa-generated induced Foxp3+ T reg cells. *The Journal of experimental medicine*. 2012; 209:1723–1742. s1721. [PubMed: 22966001]
56. Yadav M, Louvet C, Davini D, Gardner JM, Martinez-Llordella M, Bailey-Bucktrout S, Anthony BA, Sverdrup FM, Head R, Kuster DJ, Ruminski P, Weiss D, Von Schack D, Bluestone JA. Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. *The Journal of experimental medicine*. 2012; 209:1713–1722. S1711–1719. [PubMed: 22966003]
57. Holderried TA, Lang PA, Kim HJ, Cantor H. Genetic disruption of CD8+ Treg activity enhances the immune response to viral infection. *Proceedings of the National Academy of Sciences of the United States of America*. 2013; 110:21089–21094. [PubMed: 24324159]
58. Zheng Y, Josefowicz S, Chaudhry A, Peng XP, Forbush K, Rudensky AY. Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate. *Nature*. 2010; 463:808–812. [PubMed: 20072126]
59. Carpenter AC, Bosselut R. Decision checkpoints in the thymus. *Nature immunology*. 2010; 11:666–673. [PubMed: 20644572]
60. Keefe R, Dave V, Allman D, Wiest D, Kappes DJ. Regulation of lineage commitment distinct from positive selection. *Science (New York, N.Y.)*. 1999; 286:1149–1153.
61. Collins A, Littman DR, Taniuchi I. RUNX proteins in transcription factor networks that regulate T-cell lineage choice. *Nature reviews. Immunology*. 2009; 9:106–115.
62. Kito A, Ono M, Naoe Y, Ohkura N, Yamaguchi T, Yaguchi H, Kitabayashi I, Tsukada T, Nomura T, Miyachi Y, Taniuchi I, Sakaguchi S. Indispensable role of the Runx1-Cbfbeta transcription complex for in vivo-suppressive function of FoxP3+ regulatory T cells. *Immunity*. 2009; 31:609–620. [PubMed: 19800266]
63. Rudra D, Egawa T, Chong MM, Treuting P, Littman DR, Rudensky AY. Runx-CBFBeta complexes control expression of the transcription factor Foxp3 in regulatory T cells. *Nature immunology*. 2009; 10:1170–1177. [PubMed: 19767756]
64. Fu W, Ergun A, Lu T, Hill JA, Haxhinasto S, Fassett MS, Gazit R, Adoro S, Glimcher L, Chan S, Kastner P, Rossi D, Collins JJ, Mathis D, Benoist C. A multiply redundant genetic switch 'locks in' the transcriptional signature of regulatory T cells. *Nature immunology*. 2012; 13:972–980. [PubMed: 22961053]
65. Wang Y, Su MA, Wan YY. An essential role of the transcription factor GATA-3 for the function of regulatory T cells. *Immunity*. 2011; 35:337–348. [PubMed: 21924928]
66. Wohlfert EA, Grainger JR, Bouladoux N, Konkel JE, Oldenhove G, Ribeiro CH, Hall JA, Yagi R, Naik S, Bhairavabhotla R, Paul WE, Bosselut R, Wei G, Zhao K, Oukka M, Zhu J, Belkaid Y. GATA3 controls Foxp3(+) regulatory T cell fate during inflammation in mice. *The Journal of clinical investigation*. 2011; 121:4503–4515. [PubMed: 21965331]
67. Sekiya T, Kondo T, Shichita T, Morita R, Ichinose H, Yoshimura A. Suppression of Th2 and Tfh immune reactions by Nr4a receptors in mature T reg cells. *The Journal of experimental medicine*. 2015; 212:1623–1640. [PubMed: 26304965]
68. Sekiya T, Kashiwagi I, Yoshida R, Fukaya T, Morita R, Kimura A, Ichinose H, Metzger D, Chambon P, Yoshimura A. Nr4a receptors are essential for thymic regulatory T cell development and immune homeostasis. *Nature immunology*. 2013; 14:230–237. [PubMed: 23334790]
69. Fassett MS, Jiang W, D'Alise AM, Mathis D, Benoist C. Nuclear receptor Nr4a1 modulates both regulatory T-cell (Treg) differentiation and clonal deletion. *Proceedings of the National Academy of Sciences of the United States of America*. 2012; 109:3891–3896. [PubMed: 22345564]
70. DuPage M, Chopra G, Quiros J, Rosenthal WL, Morar MM, Holohan D, Zhang R, Turka L, Marson A, Bluestone JA. The chromatin-modifying enzyme Ezh2 is critical for the maintenance of regulatory T cell identity after activation. *Immunity*. 2015; 42:227–238. [PubMed: 25680271]
71. DuPage M, Bluestone JA. Harnessing the plasticity of CD4(+) T cells to treat immune-mediated disease. *Nature reviews. Immunology*. 2016; 16:149–163.

72. Sawant DV, Vignali DAA. Once a Treg, always a Treg? *Immunological reviews*. 2014; 259:173–191. [PubMed: 24712466]
73. Gondek DC, Lu LF, Quezada SA, Sakaguchi S, Noelle RJ. Cutting edge: contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. *Journal of immunology (Baltimore, Md. : 1950)*. 2005; 174:1783–1786.
74. Cao X, Cai SF, Fehniger TA, Song J, Collins LI, Piwnica-Worms DR, Ley TJ. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. *Immunity*. 2007; 27:635–646. [PubMed: 17919943]
75. Ono M, Yaguchi H, Ohkura N, Kitabayashi I, Nagamura Y, Nomura T, Miyachi Y, Tsukada T, Sakaguchi S. Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1. *Nature*. 2007; 446:685–689. [PubMed: 17377532]
76. Cretney E, Kallies A, Nutt SL. Differentiation and function of Foxp3(+) effector regulatory T cells. *Trends in immunology*. 2013; 34:74–80. [PubMed: 23219401]
77. Gratz IK, Campbell DJ. Organ-specific and memory treg cells: specificity, development, function, and maintenance. *Frontiers in immunology*. 2014; 5:333. [PubMed: 25076948]
78. Burzyn D, Benoist C, Mathis D. Regulatory T cells in nonlymphoid tissues. *Nature immunology*. 2013; 14:1007–1013. [PubMed: 24048122]
79. Zheng Y, Chaudhry A, Kas A, deRoos P, Kim JM, Chu TT, Corcoran L, Treuting P, Klein U, Rudensky AY. Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control T(H)2 responses. *Nature*. 2009; 458:351–356. [PubMed: 19182775]
80. Chaudhry A, Rudra D, Treuting P, Samstein RM, Liang Y, Kas A, Rudensky AY. CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner. *Science (New York, N.Y.)*. 2009; 326:986–991.



**Figure 1. Thpok is important for Treg development in the thymus**  
 (A, D) Percentage of Foxp3<sup>+</sup> cells among total thymocytes from mice of the indicated genotype. *Thpok*<sup>fl/fl</sup> *Ltr*<sup>fl/fl</sup> *Cd4-Cre* mice and corresponding controls were *B2m*<sup>-/-</sup> to exclude MHC I-restricted cells from analyses (D). Data is from three mice of each genotype analyzed in three independent experiments (\*\*: *P*<0.01).  
 (B) Expression of intra-cellular Foxp3 vs. surface Ox40 in Foxp3<sup>+</sup> TCRβ<sup>hi</sup> CD24<sup>lo</sup> thymocytes from mice of the indicated genotype. Data is representative of four mice of each genotype analyzed in four independent experiments.

(C) Contour plots (left) show CD45.1 vs. CD45.2 expression on Foxp3<sup>-</sup> and Foxp3<sup>+</sup> TCRβ<sup>hi</sup> CD24<sup>lo</sup> thymocytes from CD45.1<sup>+</sup> *B2m*<sup>-/-</sup> host mice transplanted with a 1:1 mix of CD45.2<sup>+</sup> *Thpok*<sup>fl/fl</sup> *Cd4*-Cre (tester [Test]) and CD45.1<sup>+</sup> CD45.2<sup>+</sup> wild-type (WT) (competitor[Comp]) bone marrow. Boxes define populations of Test (purple shaded) and Comp (plain line) origin. Numbers near boxes indicate cell percentages and were used to compute Test/Comp ratios for Foxp3<sup>+</sup> and Foxp3<sup>-</sup> subsets. The bar graph shows [(Test/Comp)<sub>Foxp3<sup>+</sup></sub> / (Test/Comp)<sub>Foxp3<sup>-</sup></sub>] ratios, respectively on gated Foxp3<sup>+</sup> and Foxp3<sup>-</sup> subsets, in chimeras made with *Thpok*<sup>fl/fl</sup> *Cd4*-Cre Test bone marrow (filled bar) and in control chimeras made from *Thpok*<sup>fl/fl</sup> Test bone marrow (open bar). Data is representative of three recipients per genotype, obtained from two separate bone marrow transplants, each with one donor from each genotype (\*\*\*\*: *P*<0.0001).


(E) Percentage of CD25<sup>+</sup> Foxp3<sup>-</sup> cells among TCRβ<sup>hi</sup> thymocytes from mice of the indicated genotype. Each symbol represents one mouse; data is from eight independent experiments (\*: *P*<0.05, unpaired t-test).

(F) Expression of CD25 vs. Ox40 in CD25<sup>+</sup> Foxp3<sup>-</sup> TCRβ<sup>hi</sup> thymocytes from mice of the indicated genotype. Data is representative of two mice of each genotype analyzed two independent experiments.

(G) Bar graph (left) shows relative expression (MFI) of GITR in CD25<sup>+</sup> Foxp3<sup>-</sup> TCRβ<sup>hi</sup> thymocytes from mice of the indicated genotype. Data is expressed relative to wild type cells analyzed in the same experiment, set to 100, and is from 8 to 10 mice of each genotype analyzed in six independent experiments (\*\*\*\*: *P*< 10<sup>-4</sup>, unpaired t-test). A representative experiment is shown on the right.

(H) Expression of CD8 vs. CD4 by Foxp3<sup>+</sup> (top) or Foxp3<sup>-</sup> (bottom) TCRβ<sup>hi</sup> thymocytes of the indicated genotype. Data is summarized in (I).

(I) Percentage (thymus, top) and absolute number (spleen, bottom) of Foxp3<sup>+</sup> cells in indicated populations from control (open squares), *Thpok*<sup>fl/fl</sup> *Cd4*-Cre (filled circles), and *Thpok*<sup>fl/fl</sup> *Cd4Si*<sup>fl/+</sup> *Cd4*-Cre (open triangles) mice. Each symbol represents an individual mouse; data is from two independent experiments. Statistical significance was determined by one-way ANOVA followed by a Tukey's multiple comparisons test (\*\*\*: *P*<0.001 \*\*\*\*: *P*<0.0001).



**Figure 2. Treg expression of Thpok or LRF is critical for immune homeostasis**

(A) LRF expression in Foxp3<sup>+</sup> spleen cells (black line). Foxp3<sup>+</sup> cells from dKO mice serve as a negative staining control (grey filled). Data is representative of three mice of each genotype analyzed in three independent experiments.

(B) Survival of *Foxp3*<sup>YFP-Cre</sup> control (grey line), Thpok KO (plain black line), dKO (red line), and Scurfy (dashed black line) male mice. Number of mice is indicated in plot. Median survival was 42 days for dKO and 24 days for Scurfy mice.

(C) Absolute number of spleen TCRβ<sup>+</sup> Foxp3<sup>+</sup> (left), Foxp3<sup>-</sup> (right) cells from control (open bars), LRF KO (grey bars), Thpok KO (black bars), or dKO (red bars) male

*Foxp3*<sup>YFP-Cre</sup> mice. Data is from at least three animals per genotype, analyzed in at least three independent experiments (control vs. dKO:  $P < 0.05$  [\*] and  $P < 0.01$  [\*\*]; other differences not significant).

(D) Hematoxylin and eosin stains on paraffin-embedded organs comparing *Foxp3*<sup>YFP-Cre</sup> control, dKO, and *Scurfy* mice, all male. Yellow scale bar is 100 $\mu$ m. Data is representative of five separate samples from mice of each genotype stained in two experiments. At time of analysis, mice were 4–6 weeks (dKO) or 2–4 weeks (*Scurfy*) old. Control mice were 6–8 weeks old.


(E) (Left) CD44 vs. CD62L expression in *Foxp3*<sup>-</sup> CD4<sup>+</sup> TCR $\beta$ <sup>+</sup> spleen cells from control or dKO male mice. (Middle and right) Expression IL-4 (middle) or IL-17 (right) vs. IFN $\gamma$  in CD4<sup>+</sup> TCR $\beta$ <sup>+</sup> spleen cells from control and dKO male mice after a 3-hour *in vitro* stimulation and intracellular cytokine staining. Data is representative of three mice of each genotype analyzed in three independent experiments.

(F) Expression of CD44 vs. CD62L on *Foxp3*<sup>-</sup> CD4<sup>+</sup> TCR $\beta$ <sup>+</sup> spleen cells from control (top) or Thpok KO (bottom) *Foxp3*<sup>YFP-Cre</sup> male mice. Data is representative of three mice of each genotype analyzed in three independent experiments.

(G) (Top) Absolute number of spleen YFP<sup>+</sup> TCR $\beta$ <sup>+</sup> cells from indicated *Foxp3*<sup>YFP-Cre</sup> mice female mice. Data is from at least three animals per genotype, analyzed in at least three independent experiments (control vs. dKO:  $P < 0.01$  [\*\*]; other differences not significant).

(Bottom) Expression of YFP in CD25<sup>+</sup> spleen T cells from control and dKO female mice.

(H) CD8 vs. CD4 expression in *Foxp3*<sup>+</sup> TCR $\beta$ <sup>+</sup> cells from control, LRF KO (top), Thpok KO (middle), or dKO (bottom) male mice. Data is representative of at least three mouse sets analyzed in at least three independent experiments.



**Figure 3. Runx3 independent impact of Thpok and LRF on Treg function**

(A) Immunoblot analysis of Runx protein expression in sorted CD44<sup>lo</sup> CD25<sup>-</sup> naive CD4<sup>+</sup> and CD8<sup>+</sup> cells from WT mice and in YFP<sup>+</sup> Tregs from control, *Thpok* KO or dKO male mice. Each lane is from 10<sup>5</sup> cells, and expression of  $\beta$ -actin is shown as a loading control. Data is representative of two biological replicates for each sample.

(B) Survival curve of control (grey line) or *Thpok*<sup>fl/fl</sup> *Lrf*<sup>fl/fl</sup> *Runx3*<sup>fl/fl</sup> (black line) *Foxp3*<sup>YFP-Cre</sup> male mice. Number of mice is indicated in plot. Median survival for *Foxp3*<sup>YFP-Cre</sup> *Thpok*<sup>fl/fl</sup> *Lrf*<sup>fl/fl</sup> *Runx3*<sup>fl/fl</sup> is 50 days. Data from control mice is the same as in Fig. 2B and shown for comparison purposes.

(C) CD8 vs. CD4 expression is shown on Foxp3<sup>+</sup> T cells from control or *Thpok*<sup>fl/fl</sup> *Lrf*<sup>fl/fl</sup> *Runx3*<sup>fl/fl</sup> *Foxp3*<sup>YFP-Cre</sup> male mice. Data is representative of three mice of each genotype analyzed in three independent experiments.


Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript





#### Figure 4. Impact of Thpok and LRF on Treg stability

(A, B) Bar graphs show relative expression (mean fluorescence intensity, MFI) of intra-cellular Foxp3 protein in YFP<sup>+</sup> spleen cells from female mice (A) or in Foxp3<sup>+</sup> spleen cells from male mice (B) of the indicated genotype; data is expressed relative to WT set to 100 within each experiment, and is from three (A) or five (B) mice of each genotype analyzed in three (A) or five (B) independent experiments (\*\*:  $P < 0.01$ ). Right panel in (B) shows a representative experiment; actual MFI of intra-cellular Foxp3 staining is indicated in each plot.


(C) Expression of CD8α vs. CD4 on Foxp3<sup>-</sup> spleen (left) or siLP (right) TCRβ<sup>+</sup> cells from control (top), Thpok KO (middle) or dKO (bottom) male mice. Data is representative of three mice of each genotype analyzed in three independent experiments.

(D) Absolute numbers of TCRβ<sup>+</sup> Foxp3<sup>-</sup> (left, male *Foxp3*<sup>YFP-Cre</sup> mice) or TCRβ<sup>+</sup> YFP<sup>-</sup> (right, female *Foxp3*<sup>+/YFP-Cre</sup> mice) CD4<sup>+</sup> CD8α<sup>+</sup> cells in the spleen (top) or siLP (bottom) of mice of the indicated genotype. Data is from at least three animals per genotype analyzed

in at least three independent experiments (control vs. Thpok KO or dKO:  $P < 0.05$  [\*] and  $P < 0.01$  [\*\*]).

(E) Contour plots of CD8 $\alpha$  vs. CD8 $\beta$  expression on CD4<sup>+</sup>CD8 $\alpha$ <sup>+</sup> Foxp3<sup>-</sup> T cells from the spleen (left) or siLP (right) of indicated male mice. Data is representative of three mice of each genotype analyzed in three independent experiments.


(F) Expression of intra-cellular LRF in Foxp3<sup>-</sup> (top) and Foxp3<sup>+</sup> (bottom) CD4<sup>+</sup> spleen T cells from LRF KO (*Lrf*<sup>fl/fl</sup> *Foxp3*<sup>YFP-Cre</sup>, plain line) and control (*Lrf*<sup>+/+</sup> *Foxp3*<sup>YFP-Cre</sup>, grey-shaded) male mice. Data is representative of two mice.



**Figure 5. Thpok and LRF promote Treg survival**

(A) LiveDeadBlue vs. Annexin V (AnnV) staining in male control (left) or dKO (right) spleen Foxp3<sup>+</sup> cells cultured in medium as indicated. Data is representative of two mice of each genotype in two independent experiments.

(B) Graph indicates percent suppression of wild-type effector T cell proliferation by female dKO (filled squares) or control (open squares) Tregs at indicated Treg: Teff ratios with suppression by control Tregs at a 1:1 ratio set to 100. Data is from at least four animals per genotype analyzed in at least four independent experiments.



**Figure 6. Impact of Thpok and LRF on Treg gene expression**

(A) Volcano plot of RNAseq data displays ratios of dKO over WT expression (x-axis, reads per million, Log<sub>2</sub> values) vs. P-value (y-axis, -Log<sub>10</sub> values); each symbol represents a distinct locus. Colored symbols display over-expressed (right, blue) and under-expressed (left, red) genes, defined by a 2-fold or greater change in expression with a 0.05 or lesser P-value. Relevant genes are indicated.

(B) Heat map shows expression of indicated genes in dKO, CtrlG and CtrlA cells (Log<sub>2</sub> values, color scale at bottom).


(C) Venn diagram shows overlap between (i) genes under-expressed in dKO relative to control Tregs and (ii) genes under- or over-expressed in Treg relative to conventional T cells (50). Heat map (right) shows expression of 21 genes, defined in the left Venn diagrams, in dKO, CtrlG and CtrlA ( $\text{Log}_2$  values, color scale at bottom).

(D) Expression of YFP vs. Ox40, Icos or Nrp1 on YFP<sup>+</sup> TCR $\beta$ <sup>+</sup> spleen cells from control (top) and dKO (bottom) female *Foxp3<sup>+</sup>/YFP-Cre* mice. Data is representative of three mice of each genotype analyzed in three independent experiments.

(E) Relative expression (MFI) of CD25 in YFP<sup>+</sup> TCR $\beta$ <sup>+</sup> spleen cells from *Foxp3<sup>+</sup>/YFP-Cre* female control (open bar) or dKO (filled red bar) mice; data is expressed relative to control set to 100 within each experiment, and is from five mice of each genotype analyzed in five independent experiments (\*\*\*:  $P < 0.001$ ).

(F) Relative fluorescence (MFI) of pStat5 in YFP<sup>+</sup> TCR $\beta$ <sup>+</sup> spleen cells from *Foxp3<sup>+</sup>/YFP-Cre* female control (open squares) or dKO (filled red circles) mice after *in vitro* stimulation with IL-2 at the indicated concentrations; data is expressed relative to pStat5 MFI in control cells treated with 3 ng/ml IL-2, set to 100 within each experiment, and is from two independent experiments (except 0.1 ng/ml, one experiment). Error bars indicate SD.

(G) (Left) Expression of YFP vs. pStat5 on *ex vivo* gated LN T cells from control (*Thpok<sup>+/+</sup> Lrf<sup>+/+</sup>*) or dKO (*Thpok<sup>fl/fl</sup> Lrf<sup>fl/fl</sup>*) *Foxp3<sup>+</sup>/YFP-Cre* female mice; cells were fixed immediately after LN disruption. Histogram overlays (middle) show pStat5 fluorescence on YFP<sup>+</sup> cells as gated in blue boxes on left plots. Grey-shaded histograms shows isotype control staining. Data is representative of four pairs of mice analyzed in four separate experiments summarized on the right plot (\*:  $P < 0.05$ , one-tailed paired t-test).



**Figure 7. Impact of Thpok and LRF on effector Tregs**

(A) Heat map shows expression of select Treg effector genes in dKO, CtrlG and CtrlA cells (Log<sub>2</sub> values, color scale at bottom).

(B) Contour plots (left) show CD44 vs. CD62L expression on YFP<sup>+</sup> (Cre-expressing) TCRβ<sup>+</sup> spleen Tregs from control (top) or dKO (bottom) female *Foxp3*<sup>+/YFP-Cre</sup> mice. Bar plots (right) show percentage of CD62L<sup>+</sup> or CD62L<sup>-</sup> CD44<sup>hi</sup> cells in YFP<sup>+</sup> TCRβ<sup>+</sup> spleen Tregs in control (open bars), LRF KO (grey bars), Thpok KO (black bars), or dKO (red bars) female *Foxp3*<sup>+/YFP-Cre</sup> mice. Data is from at least three animals per genotype and analyzed in at least three independent experiments (control vs. dKO:  $P < 0.01$  [\*\*]; other differences not significant).

(C) *Cxcr3* expression on CD62L<sup>+</sup> (dashed line) or CD62L<sup>-</sup> CD44<sup>hi</sup> (solid line) YFP<sup>+</sup> cells in female *Foxp3*<sup>+/YFP-Cre</sup> control mice. Data is representative of three mice of each genotype analyzed in three independent experiments.

(D) Percentage (left) and absolute number (right) of siLP Foxp3<sup>+</sup> TCRβ<sup>+</sup> cells in control (open bars), LRF KO (grey bars), Thpok KO (black bars), or dKO (red bars) male mice. Data is from at least three animals per genotype and analyzed in at least three independent experiments.


Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

## Foxp3-transduced activated T cells



### Figure 8. *Thpok* and LRF support Foxp3-induced gene expression

Red-line histograms (top plots) show Nrp1 (left) and CD25 (right) expression in Foxp3-transduced MHC II-restricted CD8<sup>+</sup> T cells from  $B2m^{-/-}$   $Thpok^{fl/fl}$   $Lrf^{fl/fl}$   $Cd4-Cre$  mice (in which MHC II-restricted thymocytes differentiate into CD8<sup>+</sup> T cells and MHC I-restricted T cells fail to develop). Plain and dashed black-line histograms (middle and bottom plots) show Nrp1 and CD25 expression on Foxp3-transduced wild-type CD4<sup>+</sup> and CD8<sup>+</sup> T cells. Grey-filled histograms show Nrp1 and CD25 expression on MHC II-restricted CD8<sup>+</sup> T cells, from  $B2m^{-/-}$   $Thpok^{fl/fl}$   $Lrf^{fl/fl}$   $Cd4-Cre$  mice, transduced with an empty retroviral vector. Data is representative of two (Nrp1) or four (CD25) independent experiments.